Cancer chemoresistance may be caused by activation of the NRF2 and downstream NRF2/FTH1 or NRF2/SLC7A11 pathways, resulting in the lowering of free intracellular iron (TfR1 downregulation and ferritin upregulation) or enhanced neutralization of lipid peroxides (GPX4 and FSP1 (ferroptosis suppressor protein 1) upregulation) compared to those in drug-sensitive cells. The gene discussed is TFRC; the disease is cancer.